FDA article from 28th Feb. there's some interesting takeaways here especially around the safety issues of each of these 3 approved drugs.
https://www.fda.gov/drugs/news-events-human-drugs/cder-continues-advance-rare-disease-drug-development-new-efforts-including-accelerating-rare-disease
A couple of the links to recent drug approval for rare disease does note some similarities to Trofinetide albeit their AE's appear to be much more severe than NNZ-2566
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-prurigo-nodularis
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-drug-improve-heart-function-adults-rare-heart-condition
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-acid-sphingomyelinase-deficiency-rare-genetic-disease
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-160
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.67 |
Change
0.190(1.15%) |
Mkt cap ! $2.110B | |||
| Open | High | Low | Value | Volume |
| $16.48 | $16.77 | $16.28 | $1.795M | 108.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 73 | $16.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.68 | 127 | 3 |
View Market Depth
| Last trade - 13.16pm 28/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |